Clinical Trial Update: High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating high-dose 131I-MIBG therapy combined with vincristine and five days of irinotecan for resistant/relapsed neuroblastoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 131I-MIBG (metaiodobenzylguanidine)
• Irinotecan (Irinotecan)
• Vincristine (vincristine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED | Results posted: 2015-08-07